

Glenmark launches dry powder inhaler Tavulus in Spain

11 October 2021 | News

Tavulus is expected to provide relief to COPD patients in the country



Mumbai-based Glenmark Pharmaceuticals has launched a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) under the brand name Tavulus in Spain, for the treatment of chronic obstructive pulmonary disease (COPD).

Studies show that close to 2.5 million people suffer from COPD in Spain. Tavulus is expected to provide relief to a large patient population in the country. It is a long-acting bronchodilator that helps to open the airways and makes it easier for air to get in and out of the lungs. It also works to prevent sudden, short-term worsening of COPD symptoms.

Commenting on the launch, Vice President - Business Development of Glenmark Pharmaceuticals, Dr Jiří Havránek, says, "This inhalation therapy has been shown to significantly aid in the daily management of COPD. We hope that it improves both COPD symptoms and quality of life in those who are most affected."

In November 2017, a Glenmark European subsidiary entered into a strategic, exclusive in-licensing arrangement for marketing generic Tiotropium Bromide DPI in Western Europe and the UK. Glenmark is planning subsequent launches of the product across these markets under the brand name Tiogiva in the UK, Ireland, Sweden, Finland and Norway; Tavulus in Denmark and Netherlands; and Tiotropium Glenmark in Germany.